Candel Therapeutics Inc (NASDAQ: CADL) on Monday, soared 3.27% from the previous trading day, before settling in for the closing price of $4.9. Within the past 52 weeks, CADL’s price has moved between $3.79 and $14.60.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -43.86%. The company achieved an average annual earnings per share of 53.39%. With a float of $37.21 million, this company’s outstanding shares have now reached $49.25 million.
The extent of productivity of a business whose workforce counts for 38 workers is very important to gauge. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Candel Therapeutics Inc (CADL) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Candel Therapeutics Inc is 30.22%, while institutional ownership is 35.81%. The most recent insider transaction that took place on Jun 30 ’25, was worth 17,606. Before that another transaction happened on Mar 18 ’25, when Company’s Chief Medical Officer sold 45,316 for $8.76, making the entire transaction worth $396,995. This insider now owns 52,493 shares in total.
Candel Therapeutics Inc (CADL) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 53.39% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 33.18% during the next five years compared to -43.86% drop over the previous five years of trading.
Candel Therapeutics Inc (NASDAQ: CADL) Trading Performance Indicators
Candel Therapeutics Inc (CADL) is currently performing well based on its current performance indicators. A quick ratio of 4.64 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.34, a number that is poised to hit -0.24 in the next quarter and is forecasted to reach -1.08 in one year’s time.
Technical Analysis of Candel Therapeutics Inc (CADL)
The latest stats from [Candel Therapeutics Inc, CADL] show that its last 5-days average volume of 1.2 million was superior to 1.1 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 60.85%.
During the past 100 days, Candel Therapeutics Inc’s (CADL) raw stochastic average was set at 8.59%, which indicates a significant decrease from 34.76% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 48.73% in the past 14 days, which was lower than the 94.97% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.19, while its 200-day Moving Average is $6.44. Now, the first resistance to watch is $5.24. This is followed by the second major resistance level at $5.42. The third major resistance level sits at $5.60. If the price goes on to break the first support level at $4.88, it is likely to go to the next support level at $4.70. Assuming the price breaks the second support level, the third support level stands at $4.52.
Candel Therapeutics Inc (NASDAQ: CADL) Key Stats
Market capitalization of the company is 269.82 million based on 50,103K outstanding shares. Right now, sales total 0 K and income totals -55,180 K. The company made 0 K in profit during its latest quarter, and 7,380 K in sales during its previous quarter.
